Sort by 'listens'
Off-the-shelf Immune Drug for Aggressive Multiple Myeloma: Teclistamab
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for teclistamab in the treatment of relapsed or refractory multiple myeloma. This follows a PRIME (PRIority MEdicines) designation from the European Medicines Agency (EMA) received earlier this year. …
Developments in Personalized Medicine and New Options in Breast Cancer Treatment
In this era of personalized medicine the standard "one dose fits all" approach to cancer care has been ineffective leading to treatment failures. Personalized medicine is a new healthcare paradigm that allows physicians to choose treatment methodology optimally based on…
Early Age Onset Colorectal Cancer – Trends and Challenges
Colorectal cancer is a term that includes colon and rectal cancers, both of which originate in the lower portion of the large intestine and into the rectum. Colorectal cancer (CRC) incidence in the United States is declining rapidly overall but,…
Evolving Treatment Paradigm of Multiple Myeloma
In the past decade, the FDA has approved 13 new agents and 29 treatments for multiple myeloma, which have transformed the treatment paradigm for patients. The expanded treatment options have resulted in significantly improved outcomes. Two decades ago, the median…
Enhancing Diversity in Cancer Clinical Trials
For decades, there has been an alarming lack of diversity in cancer clinical trials. Why does this happen, what can we do about it and how can we increase minority representation in these potentially life-saving trials are some of the…